Search Immortality Topics:

Page 10«..9101112..2030..»


Category Archives: Global News Feed

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

Joins exclusive group of innovative companies headquartered on Technion Campus Joins exclusive group of innovative companies headquartered on Technion Campus

Read this article:
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

Posted in Global News Feed | Comments Off on NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

More:
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Posted in Global News Feed | Comments Off on Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Ultimovacs ASA: Mandatory notification of trades by primary insider

Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an average price of NOK 7.8984 per share. Following these transactions, Langøya Invest AS and closely related parties hold 400,000 shares in Ultimovacs ASA.

See more here:
Ultimovacs ASA: Mandatory notification of trades by primary insider

Posted in Global News Feed | Comments Off on Ultimovacs ASA: Mandatory notification of trades by primary insider

PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

VANCOUVER, British Columbia, March 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to provide the following corporate updates.

See the original post here:
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Posted in Global News Feed | Comments Off on PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD…

– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose –

Read the rest here:
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD...

Posted in Global News Feed | Comments Off on Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD…

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

SAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis. The Arcutis sponsored research from The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai was presented in a scientific session at the American Academy of Dermatology (AAD) annual meeting (San Diego, CA, March 8 – 12) and answers key questions on the immune response and associated skin barrier disruption of seborrheic dermatitis.

More here:
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Posted in Global News Feed | Comments Off on New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction